Research has also shown ERBB2 expression in about 5–21% of cervical cancer specimen, and treatment with lapatinib and trastuzumab inhibited tumor growth significantly in a patient-derived xenograft model for cervical cancer. The gene discussed is ERBB2; the disease is cervical cancer.